It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms. Although the expression of interferon-stimulated genes (ISGs) likely mediates the inflammatory process leading to tumor rejection, it is insufficient by itself and the associated mechanisms need to be identified. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations.Ĭonverging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy b) to define the state of the science in biomarker discovery and validation. The effort will culminate on October 28 th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. Hideaki Tahara: Marimo Sato: Magdalena Thurin: Ena Wang: Lisa H Butterfield: Mary L Disis: Bernard A Fox: Peter P Lee: Samir N Khleif: Jon M Wigginton: Stefan Ambs: Yasunori Akutsu: Damien Chaussabel: Yuichiro Doki: Oleg Eremin: Wolf Hervé Fridman: Yoshihiko Hirohashi: Kohzoh Imai: James Jacobson: Masahisa Jinushi: Akira Kanamoto: Mohammed Kashani-Sabet: Kazunori Kato: Yutaka Kawakami: John M Kirkwood: Thomas O Kleen: Paul V Lehmann: Lance Liotta: Michael T Lotze: Michele Maio: Anatoli Malyguine: Giuseppe Masucci: Hisahiro Matsubara: Shawmarie Mayrand-Chung: Kiminori Nakamura: Hiroyoshi Nishikawa: A Karolina Palucka: Emanuel F Petricoin: Zoltan Pos: Antoni Ribas: Licia Rivoltini: Noriyuki Sato: Hiroshi Shiku: Craig L Slingluff: Howard Streicher: David F Stroncek: Hiroya Takeuchi: Minoru Toyota: Hisashi Wada: Xifeng Wu: Julia Wulfkuhle: Tomonori Yaguchi: Benjamin Zeskind: Yingdong Zhao: Mai-Britt Zocca: Francesco M Marincola: by the Office of International Affairs, National Cancer Institute (NCI), the " US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. ![]() Hideaki Tahara, 1 Marimo Sato, 1 Magdalena Thurin, 2 Ena Wang, 3 Lisa H Butterfield, 4 Mary L Disis, 5 Bernard A Fox, 6 Peter P Lee, 7 Samir N Khleif, 8 Jon M Wigginton, 9 Stefan Ambs, 10 Yasunori Akutsu, 11 Damien Chaussabel, 12 Yuichiro Doki, 13 Oleg Eremin, 14 Wolf Hervé Fridman, 15 Yoshihiko Hirohashi, 16 Kohzoh Imai, 16 James Jacobson, 2 Masahisa Jinushi, 1 Akira Kanamoto, 1 Mohammed Kashani-Sabet, 17 Kazunori Kato, 18 Yutaka Kawakami, 19 John M Kirkwood, 4 Thomas O Kleen, 20 Paul V Lehmann, 20 Lance Liotta, 21 Michael T Lotze, 22 Michele Maio, 23, 24 Anatoli Malyguine, 25 Giuseppe Masucci, 26 Hisahiro Matsubara, 11 Shawmarie Mayrand-Chung, 27 Kiminori Nakamura, 18 Hiroyoshi Nishikawa, 28 A Karolina Palucka, 12 Emanuel F Petricoin, 21 Zoltan Pos, 3 Antoni Ribas, 29 Licia Rivoltini, 30 Noriyuki Sato, 31 Hiroshi Shiku, 28 Craig L Slingluff, 32 Howard Streicher, 33 David F Stroncek, 34 Hiroya Takeuchi, 35 Minoru Toyota, 36 Hisashi Wada, 13 Xifeng Wu, 37 Julia Wulfkuhle, 21 Tomonori Yaguchi, 19 Benjamin Zeskind, 38 Yingdong Zhao, 39 Mai-Britt Zocca, 40 and Francesco M Marincola 3
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |